A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

NCT04050670 · Completed

Last updated 2026-05-28

This study tests how tirzepatide is absorbed in the body when injected in different areas and in people with varying body sizes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 54 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2019-09 · est. completion 2020-04

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04050670 ↗

Description as written by the study sponsor.

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Tirzepatide administered SC

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04050670 ↗